Client Services's Blog

  • Cure e-news by NPF


    Cure e-news   

     

      
    National Psoriasis Foundation: Cure e-news

    NATIONAL PSORIASIS FOUNDATION
    Cure e-news: November 2010
    34 psoriasis drugs in research pipeline 


    Phase III trials include new biologic briakinumab
     

    Bringing new drugs to market is a long and complicated process—yet one that offers hope to millions with psoriasis and psoriatic arthritis.

    In 2010, 34 new psoriasis medicines were in various stages of development.
    • Seven drugs have reached phase III clinical trials, in which thousands of volunteers take these new medications and drug developers do extensive tests to monitor side effects and see how well they work.
    • Twenty-seven drugs are in phase II clinical trials, in which several hundred volunteers are participating in studies that compare the safety and efficacy of the new medications to existing treatments.
    Learn more about the drug development process >>> 


    Promising new biologic drug

    One promising new drug is briakinumab (ABT-874), which pharmaceutical manufacturer Abbott Laboratories is testing as a treatment for psoriasis and other autoimmune diseases.

    Like the recently approved drug Stelara (ustekinumab), briakinumab is an injectable biologic drug that targets two proteins, interleukins 12 and 23, which are believed to promote the inflammation associated with psoriasis. Find out more about biologic drugs for psoriasis >>> 

    In one phase III trial, 80.7 percent of psoriasis patients receiving briakinumab injections saw their disease improve by 75 percent after 12 weeks, compared with 4.5 percent who were given a placebo. In another trial, 42.2 percent of briakinumab patients had 100 percent clearing after 24 weeks. 

    Serious side effects of briakinumab seem to occur at rates similar to two other psoriasis drugs, Enbrel (etanercept) or and methotrexate. Patients in one trial experienced "major adverse cardiovascular events"—heart attacks, strokes and other heart-related heart failure—were observed in one of the trials, all in patients who had risk factors related to heart disease. 

    Find out more about briakinumab >>> 


    Testing drugs for new uses

    The injectable biologic drug Stelara (ustekinumab) was approved for treatment of moderate to severe psoriasis in adults in 2009. Made by Centocor Ortho Biotech, Stelara is now in phase III trials for treatment of psoriatic arthritis and psoriasis in adolescents. 

    View or download the full list of psoriasis drugs in the 
    research pipeline >>>
     

    Learn more about the National Psoriasis Foundation's
    research initiatives >>>
    Phil Mickelson's psoriasis arthritis
    He has it for life, but the golf champ's early diagnosis may halt further damage.
    Read more
    Find courage in the youngest faces
    Your holiday donation helps find a cure for the hundreds of thousands of children with psoriatic disease.
    Give today
    Psoriasis and style
    Wondering what to wear this holiday season? Watch Psophisticated Style, your guide to style and psoriasis.
    Watch Now
    Introducing the Psoriasis Channel
    Watch educational videos about psoriasis treatment, research and awareness.
    Take a look
     
     

    800.723.9166 e-mail research@psoriasis.org www.psoriasis.org